Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, I	D.C. 20549	
---------------	------------	--

Check this box if no longer subject	STATEMENT OF CHANGES IN BENEFICIAL	<b>OWNERSHIP</b>
to Section 16. Form 4 or Form 5		
obligations may continue. See		

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  KIM PAUL					2. Issuer Name and Ticker or Trading Symbol Fulgent Genetics, Inc. [ FLGT ]									(Chec	k all app Direc	tor	ng Pers	10% O	wner
(Last) (First) (Middle) C/O FULGENT GENETICS, INC. 4978 SANTA ANITA AVENUE			3. Date of Earliest Transaction (Month/Day/Year) 08/16/2021									X	Officer (give title below)  CFO and Tr			Other (specify below) reasurer			
(Street) TEMPLI (City)	E CITY CA		)178( Zip)	0	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X						
		Table	1 - 1	Non-Deriva	tive	Secui	rities	Acc	quir	ed, D	isposed (	of, or	Benef	icially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye			ar) E	2A. Deemed Execution Dat if any (Month/Day/Ye		n Date, Trans Code		action			cquired (A) or )) (Instr. 3, 4 ar		Secur Benef Owne	5. Amount of Securities Beneficially Owned Following Reported		: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					С	ode	v .	Amount	(A) oi (D)	A) or Price		Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(11150: 4)			
Common	Stock			08/16/202	21				S		1,682(1)	D \$95.1		L227 <sup>(2)</sup>	227 <sup>(2)</sup> 135,783			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Executi Security or Exercise (Month/Day/Year) if any		Deemed cution Date, ny nth/Day/Year)	Transaction Code (Instr. 8) Se Ac (A) Dis of (In an		of Derive Secur Acqui (A) or Dispo	of Derivative (Market Market M		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Inst: 3 and 4)  Amour or Numbe of Title Shares		Price of rivative curity str. 5)			LO. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

- 1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019 and November 1, 2019.
- 2. The shares were sold in multiple transactions at prices ranging from \$94.6257 to \$96.0400, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

## Remarks:

/s/ Paul Kim

08/18/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.